Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-08-06

Clinical Trial Update: Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating high-dose melphalan with or without bortezomib in AL amyloidosis; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bortezomib (bortezomib)
  • Melphalan (Melphalan)

Snippet

Sponsor: Boston Medical Center | Conditions: AL Amyloidosis | Phase 3 | Status: TERMINATED | Results posted: 2018-08-06